Actinogen Medical Limited
ATGGF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $5,490 | $0 | $9,022 | $909 |
| % Growth | – | -100% | 892.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $212 |
| Gross Profit | $5,490 | $0 | $9,022 | $697 |
| % Margin | 100% | – | 100% | 76.7% |
| R&D Expenses | $7,714 | $4,583 | $6,583 | $8,953 |
| G&A Expenses | $1,051 | $976 | $824 | $908 |
| SG&A Expenses | $4,549 | $3,576 | $3,838 | $3,397 |
| Sales & Mktg Exp. | $3,498 | $2,600 | $3,013 | $2,490 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12,263 | $8,159 | $10,420 | $12,350 |
| Operating Income | -$6,773 | -$8,159 | -$1,398 | -$11,441 |
| % Margin | -123.4% | – | -15.5% | -1,258.6% |
| Other Income/Exp. Net | $210 | -$10 | -$9,112 | -$1,025 |
| Pre-Tax Income | -$6,563 | -$8,169 | -$10,510 | -$12,466 |
| Tax Expense | $0 | $0 | -$9,022 | -$909 |
| Net Income | -$6,563 | -$8,169 | -$1,488 | -$11,557 |
| % Margin | -119.6% | – | -16.5% | -1,271.3% |
| EPS | -0.002 | -0.28 | -0.001 | -0.005 |
| % Growth | 99.2% | -39,900% | 85.7% | – |
| EPS Diluted | -0.002 | -0.28 | -0.001 | -0.005 |
| Weighted Avg Shares Out | 3,042,783 | 29,175 | 2,285,135 | 2,339,293 |
| Weighted Avg Shares Out Dil | 3,041,774 | 29,175 | 2,284,913 | 2,339,293 |
| Supplemental Information | – | – | – | – |
| Interest Income | $412 | $224 | $184 | $107 |
| Interest Expense | $0 | $0 | $13 | $11 |
| Depreciation & Amortization | $179 | $162 | $163 | $212 |
| EBITDA | -$6,814 | -$8,199 | -$1,440 | -$12,243 |
| % Margin | -124.1% | – | -16% | -1,346.8% |